Eight-year data from APHINITY study show Roche's Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer

14.07.2022 - Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone receptor status; however overall survival ...

Related Keywords

Germany ,China ,United States ,American ,German ,Levi Garraway ,Institut Jules Bordet ,Forschungs Gmb ,American Society Of Clinical Oncology ,St Gallen International Breast Cancer Conference ,Head Of Global Product Development ,Breast International Group ,Frontier Science Foundation ,European Union ,German Breast Group ,European Society For Medical Oncology ,National Comprehensive Cancer Network ,European Society ,Medical Oncology ,Virtual Plenary ,Chief Medical Officer ,Global Product ,Sibylle Loibl ,Chief Executive Officer ,American Society ,Clinical Oncology ,International Breast Cancer Conference ,